“…While low liver-stage burden is usually associated with a delay in blood-stage patency, it is conceivable that the inflammatory environment-as exemplified by increase in serum levels of IL-12, IFN-γ, and MCP-1-induced following TLR9 activation can also impact blood stages as they egress out of the liver. Nonetheless, our findings that activation of TLR9 has an inhibitory effect on Pb pre-erythrocytic stages, are consistent with obser-vations that an altered, often inflammatory, pre-erythrocytic or early immune response at day 0-1 may change later host immune responses at days 5 and, thereby, reduce the incidence of ECM [49]. When we induced a TLR9-mediated immune response prior to infection with Pb iRBCs, which bypasses the liver stages of infection, animals had lower parasitemia and were completely protected against ECM.…”